Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. Results: The mean age at diagnosis for the entire cohort was 40.4AE22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7%). The C3 and C4 levels were low in 50 of 112 (44.6%) and 13 of 110 (11.8%) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively. However, 28 of 43 patients 50 years or older (65.1%) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1%), 30 of 69 (43.5%), and 9 of 67 (13.4%) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3AE20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4%) and 9 of 75 (12.0%) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2%) had progression to end-stage renal disease. Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy.
C
3 glomerulopathy (C3G) is a rare disease entity that is characterized by accumulation of complement factors in the glomeruli due to overactivation and abnormal regulation of the alternative pathway (AP) of complement. [1] [2] [3] [4] Abnormal control of the AP of complement may be due to acquired or genetic abnormalities of the complement regulatory proteins. The deposition of complement factors drives glomerular inflammation, resulting in a proliferative glomerulonephritis. 5, 6 The defining feature of C3G is the bright staining for C3 on immunofluorescence microscopy, with minimal or no staining for immunoglobulins. C3 glomerulopathy is further subdivided into C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) on the basis of the ultrastructural findings.
1,7 C3 glomerulonephritis is characterized by mesangial and capillary wall electron dense deposits, whereas DDD is characterized by dense sausage-shaped osmiophilic intramembranous and mesangial deposits.
A consensus on the defining characteristics of C3G was published only a few years ago. 1 Most of the reports on the clinical characteristics, pathology, complement evaluation, treatment, and outcomes of C3G are therefore based on individual cases or small series of patients with C3GN or DDD, although 2 larger series were recently published. 2, [8] [9] [10] [11] [12] In this article, we describe the clinical and pathological findings, triggering factors, complement abnormalities, treatment, and renal outcomes in a large series of 114 patients with C3G seen over a 10-year period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) at Mayo Clinic in Rochester, Minnesota.
PATIENTS AND METHODS
We identified 114 patients with a diagnosis of C3G (C3GN or DDD) on native kidney biopsies evaluated at Mayo Clinic from January 1, 2007, through December 31, 2016 . As such, this represents patients actually seen at Mayo Clinic and not data gathered from patients whose biopsies were read at the Department of Laboratory Medicine and Pathology, Mayo Clinic, but not seen at Mayo Clinic. Most are of the white race (92 of 114 patients) and belong to an older age group (mean age, 40.4AE22.3 years). C3 glomerulopathy was defined as the presence of dominant C3 staining (!2 orders in magnitude compared to immunoglobulins) on immunofluorescence microscopy, with minimal or no staining for immunoglobulins. One author (S.S.) reviewed all kidney biopsies and reports. Clinical information was obtained from the charts. The study was approved by the Mayo Clinic Institutional Review Board and conducted in accordance to the Declaration of Helsinki.
Statistical Analyses
Statistical analyses were performed using JMP Pro software version 13.0 (SAS Institute Inc.). Continuous variables are reported as median (range) and categorical variables as number (percentage). When the normality assumption was violated, we used nonparametric tests such as the Fisher exact test, chi-square test, or Wilcoxon rank-sum/Mann-Whitney U test, as appropriate, for test variables. Statistical significance was based on a 2-sided significance level of .05. The main end points of the study were end-stage renal disease (ESRD) or doubling of the serum creatinine level from the time of C3G diagnosis. The median follow-up was calculated as the median time on study for those event-free at the end of follow-up. Renal survival probabilities were determined using the KaplanMeier method, and group comparisons for survival were performed using Wilcoxon ranksum and log-rank tests. 13 Modeling for predictors of ESRD or doubling of the serum creatinine level was performed using Cox proportional hazards methods.
For analyzing 24-hour proteinuria at diagnosis and at follow-up, the average predicted proteinuria values were considered for those patients in whom a quantitative 24-hour urine protein test was not conducted. Furthermore, treatment outcomes were defined based on a previous study by Rabasco et al 11 :
(1) complete remission (CR) was defined as estimated glomerular filtration rate (eGFR) 60 mL/min per 1.73 meters squared or greater (or return to AE15% of the baseline value if eGFR is <60 mL/min per 1.73 meters squared) and proteinuria value less than 500 mg/24 h; (2) partial remission (PR) was defined as a reduction of more than 50% proteinuria (and a proteinuria value of <3500 mg/24 hours in patients with nephrotic range proteinuria at baseline) plus stabilization (AE25%) or improvement in renal function; (3) responders were defined as more than 50% reduction in proteinuria regardless of eGFR; (4) stable disease was defined as eGFR within 10% of the baseline value and a proteinuria value of less than 1500 mg/24 h from the onset to the completion of the treatment; and (5) no response (NR) was defined as less than 50% reduction in proteinuria in patients with a proteinuria value of 1500 mg/24 h or more or 25% increase in serum creatinine level from the onset to the completion of the treatment.
Genetic Testing
Sample Preparation, Target Genomic Enrichment, and Next Generation Sequencing. For each sample, genomic DNA was extracted from peripheral blood using the Gentra Puregene Kit (Qiagen Inc.); integrity was evaluated by 1% agarose gel electrophoresis. To ensure DNA samples met our minimal quality metrics of 1.8 for 260/280 and 260/230 ratios, absorbance was measured at 230, 260 and 280 nm using a NanoDrop 1000 spectrophotometer (Thermo Scientific Inc.). The concentration of DNA was determined using the Qubit dsDNA HS Assay Kit (Life Technologies). Complement genes were analyzed by capturing the coding sequence and flanking splice sites using the SureSelect Target Enrichment System (Agilent Technologies Inc.), as described previously.
14 Library preparation was performed with the SureSelect TGE bait and SureSelectXT Reagent Kit (Agilent Technologies Inc.) by following the manufacturer's protocol. Preparation was automated using a Zephyr Workstation (PerkinElmer). Library quality and concentration were evaluated using the 2100 Bioanalyzer (Agilent Technologies Inc.). Libraries passing quality control step were pooled and sequenced on the HiSeq 2500 (Illumina Inc.) or a MiSeq Sequencer (Illumina Inc.).
Next Generation Sequencing Data Analysis. Next generation sequencing data storage and analysis were performed on dedicated computing resources maintained by the Iowa Institute of Human Genetics at the University of Iowa, as described previously.
14 Sequencing data were archived as FASTQ files on a secured storage server and then analyzed using locally implemented open-source Galaxy software on a high-performance computing cluster. Galaxy (http://galaxyproject.org/) is open-source software implemented using the Python programming language. It has been developed by the Galaxy team at Pennsylvania State University, Johns Hopkins University, Oregon Health & Science University, and the Galaxy Community. Galaxy is extensible, as new command line tools can be integrated and shared within the Galaxy ToolShed. The workflow for variant calling integrated publicly available tools: reads were mapped using the Burrows-Wheeler Alignment tool against the human reference genome GRCh37/hg19; duplicates were removed by Picard; realignment, calibration, and variant calling were performed with GATK; and variant annotation was performed with a CLCG Annotation and Reporting Tool developed by our bioinformatics team.
Variant Prioritization and Sanger Validation. Low-quality variants (depth<10 or quality by depth <5) were filtered out by quality control. 15 PhyloP, 16 MutationTaster, 17 PolyPhen2, 18 SIFT, 19 and LRT 20 were used to calculate variant-specific pathogenicity scores. All reported variants were Sanger validated.
Copy Number Variation. Copy number variations across the CFHR3-CFHR1 region (for expansion of gene symbols, see www. genenames.org) were identified using a multiplex ligation-dependent probe amplification set of 13 probes and 6 control probes, all designed following the MRC-Holland synthetic probe design protocol. Patients with deletion of CFHR3-CFHR1 were further tested for copy number variation of CFH, CFHR4, CFHR2, and CFHR5. Multiplex ligation-dependent probe amplification was performed using the SALSA multiplex ligation-dependent probe amplification Reagent kit (MRC-Holland), resolved on a 3130xl Genetic Analyzer (Life Technologies), and analyzed with GeneMapper software (Life Technologies). Each multiplex ligation-dependent probe amplification run included 8 control samples (5 healthy controls [3 women; 2 men], 2 controls with a heterozygous deletion of CFHR3-CFHR1 [1 woman; 1 man], and 1 control with a homozygous deletion of CFHR3-CFHR1).
Autoantibody Assays
Immunoglobulin Gs were purified using a Melon gel column (Thermo Fisher Scientific Inc.) or protein G (SeraCare).
C3 Nephritic Factors. C3 nephritic factors (C3Nefs) were measured by the C3 convertase stabilizing assay. This assay measures the ability of C3Nefs to stabilize surface-bound C3 convertase on sheep erythrocytes. The assay was performed as described previously.
21
C4 Nephritic Factors. C4 nephritic factors (C4Nefs) were assayed to measure the ability of patient-derived IgG to stabilize preformed C4b2a, as described previously. 22 Hemolysis of C4b2a-coated sheep erythrocytes (5Â10 8 /mL) was quantitated using increasing aliquots of patient-purified IgG, supplemented with GVB-EDTA buffer to a total volume of 250 mL.
Hemolysis was recorded as a measure of the optical density of the supernatant at l¼415 nm.
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C5 Nephritic Factors. C5 nephritic factors (C5Nefs) were measured by the C3 convertase stabilizing assay with properdin. This assay is similar to the C3 convertase stabilizing assay, although properdin is included to favor the generation of C5 convertases. To perform the assay, the convertase is allowed to decay after adding patient-purified IgG and activity is measured at 30 and 80 minutes. The results are reported as a function of hemolysis at 30 minutes. 21 Factor H and Factor B Autoantibodies. Factor H (FH) and factor B (FB) autoantibodies were detected by the enzyme-linked immunosorbent assay. In brief, either FH or FB (both at 5 mg/mL; Complement Technology Inc) was coated on a 96-well microtiter plate and allowed to sit overnight at 4 C. After washing thrice with 1Â PBST (1Â phosphate buffered saline containing 0.5% Triton-X), free reactive sites were blocked with Ultrablock (AbD Serotec) for 1 hour at room temperature. Patient serum (1:50 dilution) was added for 1 hour at room temperature. Plates were washed and incubated for 1 hour at room temperature with horseradish peroxidaseelabeled goat anti-human IgG specific for the g chain. After the final washing, enzyme activity was measured using 3,3 0 ,5,5 0 -tetramethylbenzidine and optical density was Patients with monoclonal immunoglobulin (MIg) represented approximately 37.9% of the cohort (n¼36). When patients with C3G with MIg were excluded, the mean age at diagnosis was 32.3AE20.6 years (range, 3-84 years; n¼78). The median serum creatinine level at diagnosis was 1.4 mg/dL (range, 0.3-7.9 mg/dL). Urinalysis was positive for hematuria in 68 patients (87.2%). The median proteinuria value was 2450 mg/24 h (range, 250-24,165 mg/24 h). Thirty-two patients (41.0%; 26 with C3GN and 6 with DDD) had nephrotic range proteinuria (>3500 mg/ 24 h), and 14 patients had nephrotic syndrome (11 with C3GN and 3 with DDD). Thirty-eight of 77 patients (49.4%) had low C3 levels, and 9 of 75 (12.0%) had low C4 levels. The demographic, clinical, and laboratory data of patients with C3GN and DDD without MIg (n¼78) are given in Table 2 .
C3 GlomerulopathyeAssociated Triggers and Conditions
Monoclonal Gammopathy. Ninety-five of 114 patients (83.3%) were evaluated for monoclonal gammopathy by using serum and urine electrophoresis and immunofixation tests. Of 95 patients tested, 36 patients (37.9%) had MIg in serum and/or urine. Of 43 patients 50 years or older, 28 (65.1%) were positive for MIg (Figure 1 ). C3 Glomerulonephritis. Eighty-eight of 102 patients with C3GN (86.1%) were tested for MIg; 39 of these patients were 50 years or older. Overall, 32 (36.4%) were positive for MIg (24 men; 8 women). Of 39 patients with C3GN 50 years or older, 25 (64.1%) were positive for MIg.
Dense Deposit Disease. Seven of 12 patients with DDD (58.3%) were tested for a monoclonal protein (MIg), and 4 (57.1%) were positive for MIg (1 man; 3 women). Of 4 patients with DDD 50 years or older, 3 (75%) were positive for MIg.
Infections. Of 114 patients, 33 (28.9%) had a history of infection at the time of diagnosis, of whom 3 had positive antistreptolysin O titer results and 1 borderline positive anti-DNase B titer results. All 33 patients had persistent hematuria and were diagnosed with C3G on review of kidney biopsy.
C3 Glomerulonephritis. Twenty-eight patients (27.5%) had a history of infection at the time of C3GN diagnosis, of whom 2 had positive antistreptolysin O titer results and 1 borderline positive anti-DNase B titer results. Of these patients, 16 patients had a history of upper respiratory tract infection, 9 had urinary tract infection, 1 had pneumonia, 1 had human immunodeficiency virus infection, and 1 had endocarditis. Twenty patients received antibiotics, 2 were managed conservatively, and for the remaining 6 patients, treatment history was not available.
Dense Deposit Disease. Five patients (41.7%) had a history of infection at the time of DDD diagnosis (3 had upper respiratory tract infection, 1 had pneumonia, and 1 had septic arthritis), of whom 1 had positive antistreptolysin O titer results but negative anti-DNase B titer results. Of these 5 patients, 2 received antibiotics, 1 was managed conservatively, and for the remaining 2 patients, treatment history was not available. Figure 2 .
Evaluation of the AP of Complement A total of 77 patients (67.5%) were evaluated for complement abnormalities. 21 Twenty-six of 70 (37.1%) were positive for rare or novel genetic variants in complement genes (Table 3) , and 47 of 48 (97.9%) carried known C3G-associated genetic polymorphisms in CFH and/or C3 genes. Although a genetic variant was found in 37.1% of patients, the significance of many of these variants in causing C3G is not completely known. Thirty of 69 patients (43.5%) were positive for C3Nef, and 9 of 67 (13.4%) were positive for other autoantibodies including C4Nef, C5Nef, and autoantibodies to complement factor B (CFB) and complement factor H (CFH).
C3 Glomerulonephritis. Twenty-four of 61 patients (39.3%) who underwent genetic testing carried rare or novel genetic variants in complement genes. Of these, 8 patients had a heterozygous variant in CFH gene, 2 patients had a heterozygous variant in CFI gene, 6 patients had a heterozygous variant in C3 gene, 2 patients had a heterozygous variant in C5 gene, 4 patients had a heterozygous variant in CFHR5 gene, 1 patient had a heterozygous variant in C9, 2 patients had a heterozygous variant in C8B gene, 1 patient had a heterozygous variant in C8A gene, 1 patient had a heterozygous variant in C8G gene, and 1 patient had a heterozygous variant in CFHR2 gene. The acquired drivers of disease, such as C3Nef, C5Nef, FH, and FB autoantibodies, were identified in 27 (45.8%), 1 (1.7%), 2 (3.4%), and 5 (8.5%) patients, respectively. One patient had C4Nef in addition to FB autoantibody.
Dense Deposit Disease. Two of 9 patients (22.2%) who underwent comprehensive genetic testing carried a single genetic variant in CFH (Table 3) . Seven patients (87.5%) carried common polymorphisms in CFH and C3. C3 nephritic factor was detected in 3 of 10 patients tested (30%), and FH autoantibody was present in 1 of 8 patients tested (12.5%). None of the patients with DDD had multiple abnormalities.
Single vs Multiple AP Abnormalities. Of 26 patients with genetic variants, 23 patients had a genetic variant in a single gene, 2 patients had a genetic variant in 2 genes, and 1 patient had a genetic variant in 3 genes (Table 3) 
Evaluation of the AP of Complement in
MIg-Positive vs MIg-Negative C3G. Genetic variants were more common in the MIgnegative group than in the MIg-positive group (58.5% vs 9.5%; P¼.02) (Figure 1 ). In contrast, C3Nef and other autoantibodies (CFH, CFB, C4Nef, and C5Nef) were present in both the MIg-negative group and the MIgpositive group (C3Nef: 37.8% vs 45.8% and other autoantibodies: 16.7% vs 12.5%, respectively).
Kidney Biopsy Findings
Kidney biopsy findings are summarized in Table 4 , and representative biopsy findings are presented in Figure 3 . Membranoproliferative glomerulonephritis (n¼58 [51.3%]) was the most common pattern of injury followed by mesangial proliferative glomerulonephritis (n¼38 [33.6%]). Nine biopsies (8.0%) showed glomeruli with greater than 40% crescents/fibrinoid necrosis. Of these biopsies, 1 also showed diffuse proliferative glomerulonephritis and 2 showed a membranoproliferative pattern of injury in addition to crescentic lesions. Interstitial fibrosis and tubular atrophy was minimal (<10%) in 29 (25.7%), mild (10%-25%) in 56 (49.6%), moderate (26%-50%) in 22 (19.5%), and severe (>50%) in 6 (5.3%) patients. 23 Sixty-four biopsies (56.6%) showed arteriosclerosis. Immunofluorescence microscopy showed bright (2-3þ/3) staining for C3 on all biopsies. In addition, trace-1þ immunoglobulins were present in 51 biopsies (45.1%). Electron microscopy revealed mesangial deposits in 101 C3GN biopsies (99%). Capillary wall deposits (subepithelial, subendothelial, or intramembranous) were present in 99 C3GN biopsies (97.1%). Subepithelial deposits including subepithelial humps were present in 48.5% of C3GN biopsies. An additional finding was the presence of subendothelial fluff in 5 C3GN biopsies (4.9%), indicating a component of thrombotic microangiopathy. Light microscopic features of thrombotic microangiopathy, including thrombi in glomeruli or arterioles, were not present in these biopsies. Electron microscopy revealed mesangial and capillary wall Pathogenicity prediction score using a maximum of 6 computational methodsdPhyloP, SIFT, LRT, MutationTaster, PolyPhen HDIV, and GERPþþdto assess functional significance and conservation of missense variants. A score of !4 (out of 4, 5, or 6) is generally considered to indicate that a variant is more likely to be pathogenic than benign, but pathogenicity predictions are used only as a guideline to aid interpretation and are not used solely to determine pathogenicity. Figure 4 .
TEN YEARS OF C3 GLOMERULOPATHY AT MAYO CLINIC
Of 42 patients treated with immunosuppressants, 12 received corticosteroid monotherapy and 30 received other immunosuppressants with or without corticosteroids. The most common immunosuppressants included mycophenolate mofetil (MMF) in 24 patients (30.8%), eculizumab in 7 patients (9.0%), and calcineurin inhibitors in 7 patients (9.0%). The renal outcomes (ESRD or doubling of serum creatinine levels) were worse in patients managed conservatively vs those treated with immunosuppressants (17.6% vs 23.8%; hazard ratio, 2.41; 95% CI, 0.77-7.05; P¼.12).
Among 24 patients with MMF, responses to treatments were varied (Table 6 ), and at a median duration of therapy at 9.6 months (range, 1-96.2 months), 1 achieved CR, 2 achieved PR, 4 had stable disease, 15 had NR (of whom 3 had progression to ESRD), and 2 were lost to follow-up. Similarly, of 7 patients treated with eculizumab, at a median duration of therapy at 8.5 months (range, 1.6-26.7 months), 4 exhibited a response (2 CR, 1 PR, and 1 responder) and 3 had NR (of whom 2 had progression to ESRD). Of 7 patients treated with calcineurin inhibitors (tacrolimus/cyclosporine), at a median duration of therapy at 17.4 months (range, 3.1-50.9 months), 1 achieved PR and 6 had NR (of whom 1 had progression to ESRD). Dense Deposit Disease. Of 8 patients with DDD, 3 (37.5%) were treated conservatively, 4 (50%) were treated with immunosuppressive drugs, and 1 (12.5%) presented with ESRD at diagnosis and subsequently received a kidney transplant but had recurrent DDD at 38.8 months posttransplant. Of 4 patients treated with immunosuppressants, 1 also underwent therapeutic plasma exchange during the course of DDD. The median duration of the final One patient had progression to ESRD during the course of DDD and continued on dialysis at the final follow-up. For the remaining patients with stable renal function at the final follow-up, the median serum creatinine level was 0.7 mg/dL (range, 0.3-1.7 mg/dL; n¼6); the median proteinuria value was 472 mg/24 h (range, 101-1500 mg/24 h; n¼5); and urinalysis was positive for persistent hematuria in 2 of 4 patients (50%). One patient died of pneumocystis pneumonia as a consequence of chronic immunosuppression post kidney transplant.
Predictors of ESRD or Doubling of Serum Creatinine Level
The predictors of ESRD in univariate analysis (Table 7) were serum creatinine level, proteinuria value greater than 3 g/24 h at diagnosis, severity of global glomerulosclerosis, and the extent of tubular atrophy and interstitial fibrosis. KaplanMeier analysis revealing renal survival during follow-up is shown in Figure 5 , A, with an overall median survival of patients with C3G of 90.8 months (95% CI, 45.3-201.1 months). KaplanMeier analysis revealing renal survival of patients treated conservatively and those treated with immunosuppressants is shown in Figure 5 , B (Wilcoxon rank-sum, P¼.05; log-rank, P¼.10). Kaplan-Meier analysis of renal survival revealed no difference in renal survival between DDD and C3GN (log-rank, P¼.74) (data not shown).
DISCUSSION
In this study, the largest to date of C3G, we describe the clinicopathological findings, triggering factors (monoclonal gammopathy, infections, or autoimmune diseases), complement evaluation, treatment, and follow-up of 114 patients seen at Mayo Clinic in Rochester, Minnesota. Although C3G is defined by the common denominator of glomerular C3 accumulation, our data reveal that the disease is heterogeneous and that there is a broad range of clinicopathological findings, triggering events, complement abnormalities, and renal outcomes.
There are few data comparing the incidence of C3GN with that of DDD, although Medjeral-Thomas et al 25 and Bomback et al 26 have reported that C3GN is approximately 3 to 4 times more common than DDD. In our study, however, C3GN was approximately 9 times more common than DDD, a finding that could reflect selection bias, as more adult patients are seen at Mayo Clinic. Both C3GN and DDD affected all age groups, although C3GN was more common in older patients (mean age, 41.5AE22.1 years) than was DDD (mean age, 31.5AE23.2 years) (P¼.10). Patients with C3GN and DDD alike presented with hematuria and proteinuria, the latter often in the nephrotic range. Interestingly, low C3 levels were present in only 43.0% of patients with C3GN and 58.3% of patients with DDD. C3 glomerulopathy is caused by dysregulation of the AP of complement from either acquired abnormalities or genetic factors. 27 Our results confirmed the presence of both C3Nefs and genetic variants in complement regulatory proteins in a substantial proportion of patients. Although we detected a genetic variant in 37.1% of patients, in only 9 patients (12.9 %) the variant was pathogenic or likely pathogenic and in the remainder of patients the pathogenicity was of uncertain significance. Consistent with other reports, we found the prevalence of the CFH p.Y402H polymorphism to be high and antibodies to other complement proteins such as CFH and CFB to be uncommon. 5 These differences are quite distinct from atypical hemolytic uremic syndrome, in which antibodies to CFH are frequently detected. 28 Four recent studies have reported that both C3GN and DDD are associated with monoclonal gammopathy. [29] [30] [31] [32] However, although the association of C3G with monoclonal gammopathy is documented, the prevalence of monoclonal gammopathy in patients with C3G is not well known. We found monoclonal gammopathy to be common: 37.9% of patients with C3G had monoclonal gammopathy, and in patients older than 50 years, the prevalence was 65.1%. The latter subgroup was also more likely to be positive for C3Nefs and autoantibodies to complement regulatory proteins. These findings suggest that MIg may act as an autoantibody to C3 convertase or as an autoantibody to FH, adding an additional layer to the complex pathophysiology of C3G. 33, 34 In these cases, targeting MIg and the underlying hematologic disorder may be central to treating C3G. In support of this concept, a recent study has reported that treatment of the underlying B-cell lymphoproliferative disorder with hematologic response results in higher renal response rates in patients with C3GN. 24, 35 In addition, in a recent case report of C3GN with advanced renal failure, chemotherapy and stem cell transplantation for multiple myeloma resulted in renal recovery. 36 Our study underscores that an infection, most commonly an upper respiratory tract infection, often precedes or is present at the clinical presentation of C3G. Hematuria and proteinuria persist even after resolution of the infection. Furthermore, careful review of the history often revealed exacerbation of renal disease during episodes of reinfection. The AP of complement is activated during an infection. Under normal circumstances, the AP is quickly brought under control once the infection resolves. However, in the setting of genetic variation and/or the development of acquired drivers of complement dysregulation, activation of the AP continues, with resultant deposition of complement proteins and their cleavage products in the glomeruli and ensuing inflammation. This process ultimately leads to C3G. Indeed, the term "atypical" postinfectious glomerulonephritis has been used to describe C3G occurring in the setting of infections, as an infection can "unmask" a latent underlying complement abnormality. 37, 38 Kidney biopsy findings for C3G suggest that membranoproliferative glomerulonephritis was the most common pattern of injury followed by mesangial proliferative glomerulonephritis. Crescentic and diffuse proliferative glomerulonephritis were also present, although less commonly. Only the extent of global glomerulosclerosis but not the pattern of injury (mesangial proliferative, membranoproliferative, and crescentic glomerulonephritis) was predictive of ESRD. Most biopsies featured only minimal or mild ( 25%) interstitial fibrosis and tubular atrophy. Immunofluorescence microscopy showed the hallmark bright staining for glomerular C3 in all biopsies. Trace-1þ immunoglobulins were present in 46.1% of C3GN biopsies and 36.4% of DDD biopsies. This is in keeping with other studies that also found low-intensity positive staining for immunoglobulins in a significant number of C3GN and DDD kidney biopsies. 39, 40 Electron microscopy revealed mesangial and capillary wall deposits in almost all C3GN biopsies. Subepithelial hump-like deposits were present in almost 50% of C3GN biopsies, indicating that they are not restricted to infection-related glomerulonephritis. There was no difference in C3G kidney biopsy findings of patients with vs without MIg.
A major challenge is how to best treat these patients. Rabasco with decline in proteinuria to <0.5 g/g creatinine determined by the urine protein-tocreatinine ratio) or PR (stable or improved eGFR with !50% decline in proteinuria between 0.5 and 3.5 g/g creatinine determined by the urine protein-to-creatinine ratio) concordant with MMF treatment. Stable eGFR was defined as eGFR within 15% of the baseline value. Patients were categorized as "nonresponders" if they did not achieve remission on MMF. Twenty patients (67%) were classified as responders. Of note, initial proteinuria was lower (median, 2468 mg/g creatinine) in responders than in nonresponders (median, 5000 mg/g creatinine). Although patients studied by Avasare et al were younger (median age, 25 years) and had lower proteinuria (median, 3200 mg/g creatinine) than did patients treated with MMF in the study by Rabasco et al 11 (median age, 35 years; median proteinuria value, 6500 mg/24 h), there were more patients who had progression to ESRD (10%) than were patients included in the GLOSEN study (0%).
In our study, the renal outcome (ESRD or doubling of serum creatinine level) was worse in patients managed conservatively vs those treated with immunosuppressive therapy. This is even more impressive in that patients treated with immunosuppressive therapy had a much longer follow-up than did patients treated conservatively ( Figure 5, B) . However, when evaluating the group of patients treated with MMF, our results were less impressive than those reported in the 2 studies discussed above. This may be due to the worse kidney function at baseline in our group (median creatinine level, 1.4 mg/dL) vs those in Avasare et al 12 (median creatinine level, 1.0 mg/dL), but it does not explain the discrepancy between our study and the study by Rabasco et al, which included patients of age (median age, 35 years) and kidney function (median serum creatinine level, 1.3 mg/dL) similar to those in our study. In our study vs the study by Rabasco et al, there were a similar number of patients with biopsies revealing moderate to severe interstitial fibrosis and tubular atrophy (25% vs 21%). However, our patient population with C3G without MIg had a significantly higher number of patients (58.5%) with genetic forms than did the Rabasco study population (13%). In addition, our study had a lower number of patients with C3Nef (37.8%) than did the Rabasco study (48%). Thus, it is likely that the lower response rate to MMF observed in our study was due to a population enriched with the genetic forms of C3G. Taken together, these studies suggest that patients with the autoimmune form of the disease are more likely to respond to immunosuppressive therapy including MMF than are patients with genetic forms of C3G.
The present study also reports that C3G is a heterogeneous group of diseases that reflect the common underlying pathophysiology, which is dysregulation of the AP of complement. The development of C3G likely depends on a complex interaction between triggering events and the underlying abnormalities of the AP of complement ( Figure 6 ). If the group of patients with C3G is divided on the basis of the presence or absence of monoclonal gammopathy, then in the latter subgroup, patients are younger and have both genetic and acquired abnormalities of the AP of complement. In contrast, in the monoclonal gammopathy subgroup, patients are older and are less likely to carry genetic variants in complement genes.
One of the strengths of the study is that all patients were seen at a single institution and detailed clinical and laboratory findings, kidney biopsy, treatment, and follow-up were available. A limitation of the study is that complement evaluation varied, particularly as more sophisticated and detailed testing became available only for patients diagnosed during the latter part of the study. In addition, although many mutations/variants have been previously reported in C3G, the significance of some of the mutations/variants is not known and is the subject of an ongoing study by our group.
CONCLUSION
We describe the clinical and pathological findings, triggering events, and complement abnormalities in the largest cohort of patients with C3G reported to date, along with treatment and outcome data. It is of paramount importance that each patient of C3G be evaluated for complement abnormalities and triggering factors to allow appropriate treatment to be recommended.
Abbreviations and Acronyms: AP = alternative pathway; C3G = C3 glomerulopathy; C3GN = C3 glomerulonephritis; C3Nef = C3 nephritic factor; C5Nef = C5 nephritic factor; CFB = complement factor B; CFH = complement factor H; CR = complete remission; DDD = dense deposit disease; eGFR = estimated glomerular filtration rate; ESRD = endstage renal disease; FB = factor B; FH = factor H; MIg = monoclonal immunoglobulin; MMF = mycophenolate mofetil; NR = no response; PR = partial remission 
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